Professional Biography
Kathryn A. Phillips PhD is Professor of Health Economics and Health Services Research at the University of California, San Francisco (UCSF) and Founder/Director of the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS). Dr. Phillips holds degrees from the University of California-Berkeley, Harvard, and the University of Texas at Austin and previously spent eight years working for the federal government. Dr. Phillips’ research focuses on how health care is organized, delivered, and financed in the US. She focuses on personalized medicine – targeting health care interventions to patients based on their genetics – and its impact on clinical care, health economics, and health policy. She was one of the first health economists to conduct research on personalized medicine and is considered a leader in the field. Dr. Phillips is the Principal Investigator for the TRANSPERS Center, which is a multi-million dollar effort focusing on the translation of personalized medicine into practice and policy. TRANSPERS is supported by the National Institutes of Health and several foundations. Dr. Phillips conducts cross-disciplinary research across the basic, clinical, and social sciences and also across academia, industry, and government. She has served as an adviser to many advisory groups (e.g., Institute of Medicine, President’s Council of Advisors on Science and Technology, GenomeCanada, FDA). She also consults with a number of biotech companies and venture capital firms. Dr. Phillips has published over 100 peer-reviewed articles in leading journals (e.g., JAMA, New England Journal of Medicine, Health Affairs), serves on the editorial board for five journals, and has led or participated in approximately 40 funded research grants, with continuous funding from the NIH as a Principal Investigator since 1993.
________________________________________

Selected Peer-reviewed Publications

• Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins A, Ciccarone D. The cost-effectiveness of HIV testing of physicians and dentists in the United States. JAMA. 1994;271(11):851-858.
• Phillips KA. Using genetics to target drugs: Implications for biotechnology and health policy. Health Affairs: 2006: 35(5): 1271-1280
• Phillips KA, Marshall DA, Haas JS Elkin E, Lisang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber L. Clinical Practice Patterns and Cost-Effectiveness of HER2 Testing Strategies in Breast Cancer Patients, Cancer 2009 Nov 15;115(22):5166-74.
• Phillips KA, Haas JA, Liang SY, Baker LC, Tye S, Kerlikowske K, Sakowski J, Spetz J, Sonneborn D. Are gatekeeper requirements associated with cancer screening utilization? Health Serv Res. 2004;39(1):153-178
• Evaluation of Genomic Applications in Practice and Prevention Working Group (Phillips KA and others). Evaluation Testing for Cytochrome P450 (CYP450) Polymorphisms in Adults with Non-Psychotic Depression Treated with Selective Serotonin Reuptake Inhibitors (SSRIs). Genetics in Medicine, 2007, 9(12): 819-825
• Phillips KA, Van Bebber S, Issa A. Priming the pipeline: A review of the clinical research and policy agenda for diagnostics and biomarker development, Nature Reviews Drug Discovery 2006 5(6):463-9
• Phillips KA , Van Bebber S. Regulatory perspectives on pharmacogenomics: A review of the literature on key issues faced by the US FDA. Medical Care Research and Review 2006: 63(3):301-326.
• Phillips KA, Flatt SJ, Morrison KR, Coates TJ. Potential use of home HIV testing. N Engl J Med. 1995;332(19):1308-1310
• Phillips KA, Van Bebber S. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005 June;4:500-509
• Phillips KA , Mayer M, Aday LA. Barriers to care among racial/ethnic groups under managed care. Health Aff (Millwood). 2000 Jul-Aug;19(4):65-75.
• Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions . Pharmacogenomics. 2004 Dec;5(8):1139-49.
• Phillips KA, Kerlikowske K, Baker L, Chang S, Brown M. Factors associated with women''s adherence to mammography screening guidelines. Health Serv Res. 1998;33(1):29-53
• Phillips KA. Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice. JAMA 2008: 300(21): 2522-2544.
• Phillips KA, Shlipak M, Coxson P, Goldman L, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA. 2000; 284(21): 2748-2754
• Phillips KA , Veenstra DL, Ramsey S, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004 :10(7) :425-432.
• Phillips KA , Veenstra DL, Sadee W, Oren E, Lee JK. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270-2279.
• Lurie P, Avins AL, Phillips KA, Kahn J, Lowe R, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA. 1994;272(23):1832-1838
• Phillips KA , Morrison K, Andersen R, Aday L. Understanding the context of healthcare utilization: assessing environmental and provider-related variables in the behavioral model of utilization. Health Serv Res. 1998;33 (3):571-596.
• Phillips KA, Liang SY, Ladabaum L, Haas J, Kerlikowske K, Lieberman D, Hiatt R, Nagamine M, Van Bebber SL. Trends in Colonoscopy for Colorectal Cancer Screening. Medical Care 2007: 45: 160-167
• Phillips KA, Van Bebber SL, Issa AM. Building an evidence base for personalized medicine’s translation to clinical practice and health policy. Personalized Medicine 2006, 3(4): 411-414